Zealand Pharma As Stock Net Income
| ZLDPF Stock | USD 64.08 1.48 2.36% |
As of the 10th of February, Zealand Pharma maintains the Standard Deviation of 3.17, market risk adjusted performance of 0.354, and Mean Deviation of 1.87. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of Zealand Pharma AS, as well as the relationship between them. Please check out Zealand Pharma AS coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and skewness to decide if Zealand Pharma AS is priced fairly, providing market reflects its latest price of 64.08 per share. Given that Zealand Pharma AS has information ratio of (0.08), we strongly advise you to confirm Zealand Pharma AS's prevalent market performance to make sure the company can sustain itself at a future point.
Zealand Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Zealand Pharma's valuation are provided below:Zealand Pharma AS does not presently have any fundamental gauges for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Zealand |
Zealand Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Zealand Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Zealand Pharma.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Zealand Pharma on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Zealand Pharma AS or generate 0.0% return on investment in Zealand Pharma over 90 days. Zealand Pharma is related to or competes with ALK-Abelló A/S, Shanghai Junshi, InnoCare Pharma, H Lundbeck, Laboratorios Farmaceuticos, Genscript Biotech, and Hikma Pharmaceuticals. Zealand Pharma AS, a biotechnology company, engages in the discovery, development, and commercialization of peptide-base... More
Zealand Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Zealand Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Zealand Pharma AS upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.29 | |||
| Value At Risk | (8.45) | |||
| Potential Upside | 5.51 |
Zealand Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zealand Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Zealand Pharma's standard deviation. In reality, there are many statistical measures that can use Zealand Pharma historical prices to predict the future Zealand Pharma's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | 0.344 |
Zealand Pharma February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | 0.354 | |||
| Mean Deviation | 1.87 | |||
| Coefficient Of Variation | (1,895) | |||
| Standard Deviation | 3.17 | |||
| Variance | 10.04 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.53) | |||
| Treynor Ratio | 0.344 | |||
| Maximum Drawdown | 16.29 | |||
| Value At Risk | (8.45) | |||
| Potential Upside | 5.51 | |||
| Skewness | (0.91) | |||
| Kurtosis | 3.21 |
Zealand Pharma AS Backtested Returns
Zealand Pharma AS shows Sharpe Ratio of -0.11, which attests that the company had a -0.11 % return per unit of risk over the last 3 months. Zealand Pharma AS exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Zealand Pharma's Mean Deviation of 1.87, standard deviation of 3.17, and Market Risk Adjusted Performance of 0.354 to validate the risk estimate we provide. The firm maintains a market beta of -0.52, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Zealand Pharma are expected to decrease at a much lower rate. During the bear market, Zealand Pharma is likely to outperform the market. At this point, Zealand Pharma AS has a negative expected return of -0.3%. Please make sure to check out Zealand Pharma's jensen alpha, as well as the relationship between the skewness and day median price , to decide if Zealand Pharma AS performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.04 |
Virtually no predictability
Zealand Pharma AS has virtually no predictability. Overlapping area represents the amount of predictability between Zealand Pharma time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Zealand Pharma AS price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Zealand Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 10.59 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Zealand Pharma AS reported net income of (1.02 Billion). This is 398.33% lower than that of the Healthcare sector and significantly lower than that of the Biotechnology industry. The net income for all United States stocks is significantly higher than that of the company.
Zealand Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zealand Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Zealand Pharma could also be used in its relative valuation, which is a method of valuing Zealand Pharma by comparing valuation metrics of similar companies.Zealand Pharma is currently under evaluation in net income category among its peers.
Zealand Fundamentals
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 1.45 B | |||
| Shares Outstanding | 51.28 M | |||
| Shares Owned By Insiders | 0.07 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Price To Earning | 4.03 X | |||
| Price To Book | 27.79 X | |||
| Price To Sales | 5.19 X | |||
| Revenue | 292.57 M | |||
| Gross Profit | 173.75 M | |||
| EBITDA | (982.6 M) | |||
| Net Income | (1.02 B) | |||
| Cash And Equivalents | 864.44 M | |||
| Cash Per Share | 18.68 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.96 % | |||
| Current Ratio | 3.83 X | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (3.26) X | |||
| Target Price | 22.4 | |||
| Number Of Employees | 203 | |||
| Beta | 0.95 | |||
| Market Capitalization | 1.57 B | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | (1.24 B) | |||
| Working Capital | 356 M | |||
| Current Asset | 408 M | |||
| Current Liabilities | 52 M | |||
| Z Score | 1.2 | |||
| Net Asset | 2.07 B |
About Zealand Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Zealand Pink Sheet
Zealand Pharma financial ratios help investors to determine whether Zealand Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.